You are here: Industry Insights > Aspen

News List

South Africa’s Aspen Pharmacare boosts Africa’s healthcare distribution market with new deals Shem Oirere
November 16, 2023
Aspen Pharmacare Holdings Ltd continues to scale up medical distribution deals with international drug manufacturers as it seeks to increase its share of the healthcare distribution market in South Africa and rest of Sub-Saharan Africa.
Aspen to get up to $713m to produce Covid-19 vaccines for African nations pharmaceutical-technology
July 02, 2021
Aspen Pharmacare is set to receive a long-term funding package of nearly $713m (€600m) to boost the production of Coivd-19 vaccines for countries in the African continent.
First bronchiectasis patient dosed in Phase III trial to study brensocatib europeanpharmaceuticalreview
December 04, 2020
The first patient with bronchiectasis has been dosed in the Phase III ASPEN study of brensocatib, a reversible inhibitor of dipeptidyl peptidase 1.
Mylan to acquire Aspen’s thrombosis business for $757m pharmaceutical-technology
September 18, 2020
Mylan has agreed to acquire Aspen Pharmacare’s thrombosis business-related intellectual property and commercialisation rights in Europe for €641.9m ($757m).
Mylan Pays $763M for Aspen's Thrombosis Business in Europe contractpharma
September 15, 2020
Mylan N.V. has reached an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited's thrombosis business in Europe for approximately $763 million, subject to customary closing conditions ...
CMA levies fines of £2.3m in pharma probe pharmatimes
July 10, 2020
The UK's Competition and Markets Authority (CMA) has now formally concluded that three pharmaceutical companies - Aspen, Tiofarma, and Amilco - took part in an illegal arrangement that inflated the price of life-saving medicine fludrocortisone.
Drug supplier Aspen to pay NHS £8m after competition probe europeanpharmaceuticalreview
August 16, 2019
The CMA alleges that Aspen broke competition law, prompting the drug supplier to offer a payment and other compensations to the NHS.
Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia americanpharmaceuticalreview
June 27, 2018
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions
Aspen to acquire remaining rights to AstraZeneca’s anaesthetic medicines pharmaceufical-technology
September 19, 2017
Aspen Global Incorporated (AGI) has entered an agreement to acquire all the remaining rights to AstraZeneca’s established anaesthetic treatments for an upfront consideration of $555m.
Roche, Pfizer and Aspen under investigation over cancer drug pricing pharmaceutical-technology
June 21, 2017
The Competition Commission of South Africa has initiated separate investigations against three global pharmaceutical companies over suspected excessive pricing of cancer medicines.

Previous page 1 2 Next page